US 11578078
Heterocyclic RIP1 inhibitory compounds
granted A61PA61P29/00A61P37/00
Quick answer
US patent 11578078 (Heterocyclic RIP1 inhibitory compounds) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61P, A61P29/00, A61P37/00, A61P39/00